Phibro Animal Health Corporation (PAHC) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance, with notable growth in net sales and adjusted EBITDA, especially in the Animal Health segment. The optimistic guidance and strategic initiatives, such as the Phibro Forward Initiative and Zoetis portfolio contributions, support a positive outlook. Despite some uncertainties in growth sustainability, management's confidence in demand and profitability, along with strategic expansions into companion animals, suggest a favorable market reaction. The decision not to update guidance reflects caution rather than negative sentiment, aligning with a positive stock price outlook.
Key Financial Performance
Consolidated Net Sales $363.9 million, reflecting an increase of $103.5 million or a 40% increase year-over-year. The increase was driven by the Animal Health segment's 55% growth, Mineral Nutrition's 7% growth, and offset by a 7% decline in Performance Products.
Animal Health Segment Net Sales $283.5 million, an increase of $100.9 million or 55% year-over-year. Growth was driven by the new MFA business contributing $80.5 million, legacy MFA's 6% growth, Nutritional Specialties' 13% growth, and Vaccines' 25% growth.
Adjusted EBITDA Increased by $31.2 million or 102% year-over-year. This was driven by increased gross profit from sales growth, partially offset by higher adjusted SG&A and interest expenses.
Animal Health Adjusted EBITDA $74.9 million, an 85% increase year-over-year. Growth was driven by the new MFA business and improved mix in the legacy business, partially offset by higher SG&A.
Mineral Nutrition Net Sales $63 million, an increase of $3.9 million or 7% year-over-year. Growth was due to increased demand for copper and trace minerals.
Performance Products Net Sales $17.4 million, a decrease of $1.4 million or 7% year-over-year. The decline was due to lower demand for ingredients used in personal care products.
Free Cash Flow $34 million for the 12 months ended September 30, 2025. This was generated from $77 million of operating cash flow and $43 million in capital expenditures.
Cash and Cash Equivalents $85 million at the end of the quarter.
Gross Leverage Ratio 3.3x at the end of the first quarter, based on $749 million of total debt and $227 million of trailing 12 months adjusted EBITDA.
Net Leverage Ratio 2.9x at the end of the first quarter, based on $664 million of net debt and $227 million of trailing 12 months adjusted EBITDA.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Launch of Restoris: Introduced a proprietary dental gel for dogs, marking a significant milestone in the companion animal strategy.
New therapeutic compound: Licensed an early-stage therapeutic compound targeting canine periodontal disease, building a differential oral care portfolio.
Animal Health segment growth: Achieved 55% growth in Animal Health sales, driven by Medicated Feed Additives (81% growth), nutritional specialties (13% growth), and vaccines (25% growth).
Vaccine demand: Increased demand for poultry products in Latin America and higher international demand.
Phibro Forward initiatives: Enhanced operational discipline, accelerated innovation, and sharpened focus on strategic growth, enabling investment in high-impact opportunities.
Integration of MFA portfolio: Successfully integrated the acquired Medicated Feed Additive portfolio, contributing significantly to sales and EBITDA growth.
Focus on innovation and execution: Continued emphasis on innovation and execution to drive sustainable long-term value creation.
Phibro Forward income growth initiative: Focused on unlocking additional revenue growth and cost savings, with onetime consulting fees included in GAAP guidance.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Performance Products Segment Decline: Net sales in the Performance Products segment decreased by 7%, driven by lower demand for ingredients used in personal care products. This decline could impact overall revenue and profitability.
Higher SG&A Costs: Increased selling, general, and administrative expenses, particularly due to higher employee-related costs, could pressure margins and reduce profitability.
Increased Interest Expense: Higher adjusted interest expenses were noted, which could impact net income and financial flexibility.
Corporate Expense Growth: Corporate expenses increased by $3.4 million, driven by higher employee-related costs, which could strain operational budgets.
Leverage Ratios: The gross leverage ratio stands at 3.3x, and the net leverage ratio is 2.9x, indicating a significant level of debt that could pose risks in a rising interest rate environment or economic downturn.
One-Time Costs for Phibro Forward Initiative: The Phibro Forward income growth initiative includes one-time consulting fees, which could temporarily impact GAAP net income and EPS.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Fiscal Year 2026 Net Sales Guidance: Net sales are projected to remain in the range of $1.425 billion to $1.475 billion, representing a growth range of 10% to 14% with a midpoint of approximately 12%.
Fiscal Year 2026 Adjusted EBITDA Guidance: Adjusted EBITDA is expected to increase to a range of $230 million to $240 million, representing a growth range of 25% to 30% with a midpoint of approximately 28%.
Fiscal Year 2026 Adjusted Net Income Guidance: Adjusted net income is projected to increase to a range of $108 million to $115 million, representing growth of 26% to 34% with a midpoint of approximately 31%.
Phibro Forward Initiative Impact: The initiative is expected to drive additional EBITDA and margin growth through revenue growth and cost savings. Onetime costs related to this initiative are included in the GAAP guidance.
Market Trends and Consumer Preferences: Emerging research indicates that GLP-1 users are increasingly choosing high-quality animal-derived proteins, supporting long-term growth in the animal health industry.
Companion Animal Strategy: The launch of Restoris, a proprietary dental gel for dogs, and a newly licensed early-stage therapeutic compound targeting canine periodontal disease are expected to drive long-term growth in the companion animal segment.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Quarterly Dividend: Consistent with our history, we paid a quarterly dividend of $0.12 per share or $4.9 million in aggregate.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How are you thinking about the sustainability of growth in the legacy MFA business, and what is the appropriate run rate for this business?
A:Larry Miller stated that there is continued strong demand across the MFA portfolio, particularly in poultry, swine, and beef cattle segments, driven by protein consumption growth. Glenn David added that in Q1, growth was primarily volume-driven with limited price impact, but price improvements, especially for Zoetis products, are expected to contribute to profitability in future quarters.
Q:What is the margin profile for the remainder of the year, and are there any dynamics from an expense perspective to consider?
A:Glenn David explained that Q1 margins benefited from a favorable mix, with strong growth in higher-margin products like vaccines (25%) and nutritional specialties (13%). Expenses were also lower than expected due to timing. However, margins are expected to drop slightly as investments in new product launches, such as Restoris, increase in future quarters.
Q:Why was the revenue guidance not updated despite a strong top-line performance in Q1?
A:Glenn David mentioned that while Q1 showed strong top-line performance, the decision not to update revenue guidance was due to being only one quarter into the year. The updated guidance reflects favorable expenses and mix from Q1.
Q:Can you elaborate on the licensing for the dental asset and its fit into the company's strategy?
A:Daniel Bendheim explained that the company licensed a long-term pharmaceutical product and launched Restoris, a medical device for treating periodontal disease in dogs. Restoris allows vet techs to perform procedures, freeing up vets for higher-value tasks. The company sees dental as an unmet need in the companion animal market and plans to follow up with a licensed product for preventive care.
Q:What is driving strong livestock demand, and how sustainable is it?
A:Larry Miller attributed strong livestock demand to a resurgence in animal-based protein consumption, supported by global population growth, changing dietary preferences, and lower feed costs. He noted that livestock sector profitability remains strong globally, and Phibro is well-positioned with its geographic presence and product offerings to meet this demand.
Q:What drove better-than-expected growth in the legacy business, and were there any nonrecurring items?
A:Glenn David stated that strong performance was seen across legacy MFA, nutritional specialties, and vaccines, with no significant nonrecurring items. Some larger customer purchases in Q1 may have slightly impacted results but are not material.
Q:Does the Lighthouse licensing agreement and Restoris signal a higher focus on companion animals, and what is the company's BD strategy?
A:Daniel Bendheim clarified that while the main focus remains on production animals, the company is exploring unique opportunities in the companion animal market, particularly in areas not targeted by larger players.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the sustainability of growth in the legacy MFA business by not providing a clear underlying run rate or specific timing dynamics. Additionally, the decision not to update revenue guidance despite strong Q1 performance was attributed to conservatism, but lacked detailed explanation of potential headwinds.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Additives way
Forward effort
GLP user
Health Webcast
Health evidence
Officer remark
Phibro offering
Phibro term
ability demand
animal health
animal protein
animal stage
approach future
canine disease
care portfolio
compound canine
consumer preference
creation launch
demand line
detail approach
discipline focus
disease care
dog milestone
effort discipline
evidence Additives
flexibility opportunity
focus flexibility
food quality
future animal
gain specialty
gel dog
health portfolio
legacy
value
PAHC Transcript
Phibro Animal Health Corporation (PAHC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Phibro Animal Health Corporation (PAHC) Q3 2026 Earnings Call Transcript
Unknown5-7
The earnings call summary presents a mixed picture. Positive elements include increased revenue, EBITDA, and net income guidance, as well as growth in the Animal Health and Mineral Nutrition segments. However, geopolitical volatility, foreign currency losses, and increased interest expenses pose risks. The Q&A section highlighted minimal impact from the Middle East conflict and a conservative guidance approach. Performance Products segment decline and inventory buildup are concerns. Overall, the positive and negative factors balance each other, leading to a neutral stock price prediction.
Phibro Animal Health Corporation (PAHC) Q2 2026 Earnings Call Transcript
Positive2-5
The earnings call summary and Q&A reveal strong financial performance, optimistic guidance, and strategic initiatives like the Phibro Forward, which are expected to drive growth. Despite some concerns over inventory buildup and unclear management responses on specific details, the overall sentiment is positive due to robust margins, favorable market trends, and promising product launches. The positive reception of Restoris and share gains in key segments further bolster the outlook, suggesting a likely stock price increase in the short term.
Phibro Animal Health Corporation (PAHC) Q1 2026 Earnings Call Transcript
Positive11-6
The earnings call reveals strong financial performance, with notable growth in net sales and adjusted EBITDA, especially in the Animal Health segment. The optimistic guidance and strategic initiatives, such as the Phibro Forward Initiative and Zoetis portfolio contributions, support a positive outlook. Despite some uncertainties in growth sustainability, management's confidence in demand and profitability, along with strategic expansions into companion animals, suggest a favorable market reaction. The decision not to update guidance reflects caution rather than negative sentiment, aligning with a positive stock price outlook.
PAHC Slides
PAHC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
